| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2004;35:1941.)
© 2004 American Heart Association, Inc.
Original Contributions |
From the Durham VA Medical Center (L.B.G., D.B.M.), the Department of Medicine (Neurology [L.B.G.] and General Internal Medicine [G.P.S., D.B.M.]), the Stroke Policy Program, Center for Clinical Health Policy Research (L.B.G., G.P.S., D.B.M.), and the Center for Cerebrovascular Disease (L.B.G., G.P.S., D.B.M.), Duke University, Durham, NC; and the Office of Minority Health and Research (R.D.H.), National Institute of Neurological Disorders and Stroke, Bethesda, Md.
Correspondence to Dr Larry B. Goldstein, Director of Duke Center for Cerebrovascular Disease, Head of Stroke Policy Program, Center for Clinical Health Policy Research, Box 3651, Duke University Medical Center, Durham, NC 27710. E-mail golds004{at}mc.duke.edu
| Abstract |
|---|
|
|
|---|
Methods The Department of Veterans Affairs (VA) Stroke Study prospectively identified stroke patients admitted to 9 VA hospitals between April 1995 and March 1997. The Charlson Index was scored on the basis of discharge International Classification of Diseases, 9th Revision, Clinical Modification coding and dichotomized (low comorbidity 0 or 1 versus high
2) for analysis. Validity was assessed on the basis of modified Rankin score at hospital discharge (good outcome 0 or 1 versus poor
2 or dead) and 1-year mortality, adjusting for initial stroke severity.
Results Of the 960 enrolled ischemic stroke patients, 23% had a Charlson Index of 0, 34% 1, 22% 2, 12% 3, and 8%
4. Forty-eight percent of those with a low Charlson Index had a good outcome at discharge versus 37% of those with a high Charlson Index (P<0.001). For 1-year mortality, the proportions were 16% versus 26%, respectively (P<0.001). Logistic regression adjusting for initial stroke severity showed that those with a high Charlson Index had 36% increased odds of having a poor outcome at discharge (P=0.038) and 72% greater odds of death at 1 year (P=0.001). Every 1-point increase in Charlson Index was independently associated with a 15% increase in the odds of a poor outcome at discharge (P<0.005) and a 29% increase in the odds of death by 1 year (P<0.001).
Conclusions These data support the validity of the Charlson Index as a measure of comorbidity for use in ischemic stroke outcome studies.
Key Words: stroke outcome morbidity mortality outcome assessment
| Introduction |
|---|
|
|
|---|
|
| Subjects and Methods |
|---|
|
|
|---|
Subjects
A research assistant identified patients with possible stroke within 48 hours of hospital admission by screening admission logs. The diagnosis was then confirmed by review of medical records and discussion with the patients attending physician. This patient identification method was supplemented by review of the hospital discharge files for diagnoses of intracerebral hemorrhage (ICD-9-CM code 431) or acute cerebral infarction (ICD-9-CM code 434 or 436). In addition, all discharge ICD-9-CM codes were recorded. Patients whose stroke was iatrogenic because of brain trauma or neoplasm, occurred during hospitalization for other medical conditions, was an extension of a previous stroke, or occurred >7 days before admission were excluded. The present analysis focused only on patients with ischemic stroke. Those with hemorrhagic stroke were not included.
Demographic Variables and Clinical Outcome
Demographic characteristics included age, sex, and self-reported race/ethnic group (white, black, Hispanic, other). Stroke subtype was assigned using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria with the aid of a computerized system to optimize reliability.3 Stroke severity was determined retrospectively with the Canadian Neurological Scale.2,4,5 The patients functional status at hospital discharge (modified Rankin score [mRS]6) was recorded prospectively, and mortality rates at 1 year were ascertained.
Modified Charlson Index
Comorbid conditions were classified with a modified version of the Charlson Index on the basis of hospital discharge ICD-9-CM codes. (Table 1)1 Each of the indicated diagnoses is assigned a weight and summed to provide a patients total score. The original Charlson Index includes cerebrovascular disease (weight 1) and hemiplegia (weight 2). Because these items are reflected in the condition being evaluated (ie, stroke), they are not included. In addition, the Charlson Index has separate categories for mild versus moderate or severe liver disease as well as moderate or severe renal disease. Because disease severity cannot be derived from ICD-9-CM codes, liver disease codes were all categorized as reflecting mild disease, and all renal disease codes were categorized as reflecting moderate or severe disease (Table 1). Patients with diabetes and renal disease were included in the diabetes with end-organ damage category.
Statistical Analysis
The modified Charlson Index was dichotomized (low comorbidity 0 or 1 versus high
2) for analysis. The mRS was also dichotomized as commonly used in stroke outcome studies (good outcome, mRS 0 or 1 versus poor outcome, mRS
2 or dead). The relationships between the unadjusted modified Charlson Index and functional status at hospital discharge as well as 1-year mortality were determined. Multivariable logistic regression was then used to determine the independent effect of Charlson Index on each outcome, controlling for stroke severity.
| Results |
|---|
|
|
|---|
The patient mean age was 68.1 (±9.5) years with 68.8% whites, 27.7% blacks, and 3.2% Hispanics. Comorbid conditions by history included diabetes in 36.0%, hypertension in 58.1%, ischemic cardiac disease in 26.0%, atrial fibrillation in 12.7%, and congestive heart failure in 7.7%. More than 76% of the patients had a history of cigarette smoking. On the basis of the TOAST classification scheme, 13.5% of patients had large-vessel atherothrombotic, 18.8% cardioembolic, and 24.7% lacunar subtypes, with the remainder having strokes of undetermined or multiple causes. Because this was a veteran population, only 1.6% of the patients were women. The mean admission Canadian Neurological Scale score was 8.4 (±2.5). Figure 1 gives the distribution of Charlson Index scores for the entire cohort (57.4% of patients had Charlson scores of either 0 or 1. Overall, 7.9% of patients died by 1 month after stroke, and 20.8% died by 1 year. Among patients surviving at discharge, 15.8% had an mRS of 0; 31.9%, 1; 3.5%, 2; 13.0%, 3; 27.6%, 4; and 8.1% had an mRS of 5.
|
Table 1 gives the proportion of patients having each condition on the basis of the indicated discharge ICD-9-CM codes. Other ICD-9-CM codes that may appropriately reflect diagnoses within the indicated categories exist but were not used for any patient in this cohort. Table 1 also gives the frequencies that each ICD-9-CM code was assigned. Table 2 gives ICD-9-CM codes used in >1% of the patients in the cohort, the proportions of patients (n=960) assigned each code, and the proportion of patients with a condition included in each category accounted for by each code. Figure 2 gives the univariable relationships between the modified Charlson Index and the mRS at hospital discharge and 1-year mortality.
|
|
Logistic regression adjusting for initial stroke severity showed that those with a high Charlson Index (ie,
2) had 36% increased odds of having a poor outcome (mRS
2) at discharge (P=0.038) and 72% greater odds of death at 1 year (P=0.001). The relationship between Charlson Index and discharge status remained if the Rankin Index was considered as a full rather than a dichotomized scale. Every 1-point increase in the Charlson Index was associated independently with a 15% increase in the odds of a poor outcome at discharge (P<0.005) and a 29% increase in the odds of death by 1 year (P<0.001). A high Charlson Index was also associated with 32% increased odds of death at hospital discharge (P=0.266) and 60% increased odds of 30-day mortality (0.066), but the differences were not significant after adjustment for stroke severity (P<0.001). Inclusion of age as a covariate yielded essentially equivalent results. (Compared with models that included only severity, the odds ratios for the Charlson Index in models that controlled for both age and severity increased by 0.9% to 3.5%.)
| Discussion |
|---|
|
|
|---|
There are a variety of parameters that may reflect the validity of a scale. Content validity indicates how well a scale includes domains thought to be relevant to a condition. Convergent validity is demonstrated when scales or items that are thought to measure the same construct have high correlation coefficients. Divergent validity is demonstrated when items or scales thought to measure different constructs have low correlation coefficients. In this case, there is no "gold standard" measure of aggregate comorbidity for comparison, so these types of validity cannot be assessed. The present study does provide evidence of both known groups and predictive validity of the Charlson Index in this setting. Known groups validity tests for differences in scores from patients known to be clinically different (in this study, they are reflected in discharge status and 1-year mortality). Predictive validity reflects how well a scale predicts future events.
It should be noted that this analysis was designed to determine whether the Charlson Index would provide a valid comorbidity adjustment for stroke outcome studies and not intended to provide a clinically applicable prognostic model. A variety of such models exist that were developed to address particular questions.711 In addition, several recent studies that generally require prospective data collection have devised and tested prognostic models for use in specific settings. For example, the Combined Lysis of Thrombus in Brain Ischemia Using Transcranial Ultrasound and Systemic TPA investigators assessed the relative contributions of recanalization during the first hours of middle cerebral artery occlusion and the clinical and neuroradiological data in predicting good outcome (mRS
2) 3 months after stroke.12 Recanalization within 300 minutes (odds ratio [OR], 4.11; 95% CI, 2.42 to 6.95), baseline National Institutes of Health Stroke Scale (NIHSS) score (OR, 0.35; 95% CI, 0.16 to 0.78), stroke volume on brain computed tomography scan (Alberta Stroke Program Early CT score;13 OR, 2.98; 95% CI, 1.13 to 7.85), systolic blood pressure (OR, 0.32; 95% CI, 0.13 to 0.76), and proximal occlusion (OR, 0.25; 95% CI, 0.10 to 0.61) were associated independently with good outcome at 3 months. The German Stroke Study Collaboration validated 2 models predicting complete functional recovery (Barthel Index >95) and mortality at 3 months on the basis of patients age and NIHSS score obtained within 6 hours of symptom onset.14 Severely affected patients were not included in the analysis. The models explained 51% of the variance for complete functional recovery and 30% of the variance in mortality.
Although the Charlson Index would be useful to adjust for comorbidity in studies with prospective data collection, the present analysis supports its use in outcome studies involving large databases that often lack clinical information. These databases record comorbid diseases using ICD-9-CM codes. As shown in Table 2, a few ICD-9-CM codes accounted for the majority of conditions in each Charlson Index category. In addition to those codes actually used in stroke patients included in this cohort as reflected in the tables, other ICD-9-CM codes are available that can also reflect diseases included in the Charlson Index. It is well recognized that ICD-9-CM codes may be inaccurate, including their application to stroke conditions.1517 There was no attempt to confirm the accuracy of ICD-9-CM discharge coding for comorbid conditions as applied in the present study because such confirmation would not be feasible in large database outcome studies in which records generally cannot be linked to a patients medical records. Moreover, there may be undercoding of comorbid conditions among patients who die in the hospital. Finally, this modified version of the Charlson Index ignores previous strokes, the impact of which is only partially reflected in the Canadian Stroke Scale. Additional studies could be conducted in nonveteran populations to further investigate the utility of case-mix adjustment on the basis of the modified Charlson Index. Despite these limitations, ICD-9-CM coding remained related independently to both functional status at hospital discharge and 1-year mortality, supporting its usefulness for this purpose.
| Acknowledgments |
|---|
Received March 5, 2004; revision received May 7, 2004; accepted May 14, 2004.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
H. Zhu and M. D. Hill Stroke: The Elixhauser Index for comorbidity adjustment of in-hospital case fatality Neurology, July 22, 2008; 71(4): 283 - 287. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tang, J. Y. Wan, and J. E. Bailey Performance of Comorbidity Measures to Predict Stroke and Death in a Community-Dwelling, Hypertensive Medicaid Population Stroke, July 1, 2008; 39(7): 1938 - 1944. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Bushnell, J. Lee, P. W. Duncan, L. K. Newby, and L. B. Goldstein Impact of Comorbidities on Ischemic Stroke Outcomes in Women Stroke, July 1, 2008; 39(7): 2138 - 2140. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Driver, T. Kurth, J. E. Buring, J. M. Gaziano, and G. Logroscino Parkinson disease and risk of mortality: A prospective comorbidity-matched cohort study Neurology, April 15, 2008; 70(16_Part_2): 1423 - 1430. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Sorror, S. Giralt, B. M. Sandmaier, M. De Lima, M. Shahjahan, D. G. Maloney, H. J. Deeg, F. R. Appelbaum, B. Storer, and R. Storb Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences Blood, December 15, 2007; 110(13): 4606 - 4613. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Saposnik, A. Baibergenova, M. O'Donnell, M. D. Hill, M. K. Kapral, V. Hachinski, and On behalf of the Stroke Outcome Research Canada (S Hospital volume and stroke outcome: Does it matter? Neurology, September 11, 2007; 69(11): 1142 - 1151. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Onukwugha and C. D. Mullins Racial Differences in Hospital Discharge Disposition among Stroke Patients in Maryland Med Decis Making, May 1, 2007; 27(3): 233 - 242. [Abstract] [PDF] |
||||
![]() |
G. Saposnik, A. Baibergenova, N. Bayer, and V. Hachinski Weekends: A Dangerous Time for Having a Stroke? Stroke, April 1, 2007; 38(4): 1211 - 1215. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kumar, S. Savitz, G. Schlaug, L. Caplan, and M. Selim Antiplatelets, ACE inhibitors, and statins combination reduces stroke severity and tissue at risk Neurology, April 25, 2006; 66(8): 1153 - 1158. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Sorror, M. B. Maris, R. Storb, F. Baron, B. M. Sandmaier, D. G. Maloney, and B. Storer Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT Blood, October 15, 2005; 106(8): 2912 - 2919. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Kapral, J. Fang, M. D. Hill, F. Silver, J. Richards, C. Jaigobin, A. M. Cheung, and for the Investigators of the Registry of the Canad Sex Differences in Stroke Care and Outcomes: Results From the Registry of the Canadian Stroke Network Stroke, April 1, 2005; 36(4): 809 - 814. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Matchar and A. G. Rudd Health Policy and Outcomes Research 2004 Stroke, February 1, 2005; 36(2): 225 - 227. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |